ClinicalTrials.gg
CompletedNCT01656161Updated Sep 15, 2015Results posted

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

A Phase 3 interventional study of Triptorelin embonate 22.5 mg in Prostate Cancer, sponsored by Debiopharm International SA. Completed at 10 sites in South Africa. Open to male participants. Per ClinicalTrials.gov, last updated 2015-09-15.

Sponsored by Debiopharm International SA (part of Debiopharm) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.

Enrollment
14th of 28
120 · median 120
Started
2012
with 2 others
Phase 3
12 of 28
2 open now
Registered
12th of 28
by date
Lead sponsor
2 of 28
Debiopharm International SA

Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 14th largest by enrollment, is one of 3 that started in 2012, is one of 12 in phase 3, and was the 12th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About triptorelin

triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing triptorelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy of triptorelin embonate 22.5 mg 6-month formulation administered by the subcutaneous (under the skin) route in:

  • achieving castrate levels of testosterone (\< 1.735 nmol/L) on Day 29 [i.e., 28 days after investigational medicinal product (IMP) injection], and
  • in maintaining serum testosterone castrate levels from Month 2 (Day 57) to end of Month 12 (Day 337) in participants with advanced prostate cancer.
03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Summary Inclusion Criteria:

  • Meets protocol-specified criteria for qualification and
  • Is willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related food, drink and medications
  • Voluntarily consents to participate and provides written prior to any protocol-specific procedures

Summary Exclusion Criteria:

  • Has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters
  • Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or well-being of the participant or study staff; 2) the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3) the analysis of results
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Triptorelin embonate 22.5 mg

    Participants received subcutaneous injections of triptorelin embonate 22.5 mg 6-month formulation administered on Day 1 and on Day 169.

    Drug: Triptorelin embonate 22.5 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving and Maintaining Castrate Levels of Serum Testosterone (<1.735 Nmol/L)

    Time frame: within 337 days

Secondary outcomes

  1. Percentage of Participants Showing ≤ 1.0 IU/L Increase in Serum Luteinising Hormone (LH) From 0 Hour to 2 Hours Post-injection on Day 1 and Day 169

    Time frame: on Days 1 and 169

  2. Percentage Change From Baseline in Prostate Specific Antigen (PSA) Through Day 337

    Time frame: Baseline through Day 337

  3. Number of Participants Who Presented a Real "Acute-on-chronic" (AOC) Phenomenon (Testosterone Levels ≥ 1.735 Nmol/L 48 Hours After the Second Injection While Previously Castrated)

    Time frame: Day 171

  4. Testosterone Pharmacodynamic (PD) Metrics for First Injection: Area Under the Concentration vs Time Curve (AUC)

    Time frame: Days 1-169

  5. Testosterone PD Metrics for First Injection: Maximum Concentration (Cmax)

    Time frame: Days 1-169

  6. Testosterone PD Metrics for First Injection: Time to Peak Serum/Plasma Concentration (Tmax)

    Time frame: Days 1-169

  7. Testosterone PD Metrics for First Injection: Time to Castration (Tcast)

    Time frame: Days 1-169

  8. Triptorelin PK Metrics for Both Injections: Area Under the Concentration vs Time Curve (AUC)

    Time frame: Days 1-169 and Days 169-337

  9. Triptorelin PK Metrics for Both Injections: Cmax

    Time frame: Days 1-169 and Days 169-337

  10. Triptorelin PK Metrics for Both Injections: Concentration 0 Hour

    Time frame: Days 1-169 and Days 169-337

07

Results

Posted Sep 15, 2015

Participant flow

Participants took part in the study at 10 hospital settings in South Africa, from 03 July 2012 to 30 August 2013.

Participant flow — Overall Study
MilestoneTriptorelin Embonate 22.5 mg
Started120
Received triptorelin at day 1120
Received triptorelin at day 169115
Completed113
Not completed7
Withdrew: Death3
Withdrew: Adverse event2
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants Achieving and Maintaining Castrate Levels of Serum Testosterone (<1.735 Nmol/L)
Time frame:
within 337 days
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving and Maintaining Castrate Levels of Serum Testosterone (<1.735 Nmol/L)
Percentage of ParticipantsTriptorelin Embonate 22.5 mg
Achieving (by Day 29)98.33 (94.11 to 99.80)
Maintaining (Day 57 to Day 337)82.61 (74.43 to 89.04)
SecondaryPercentage of Participants Showing ≤ 1.0 IU/L Increase in Serum Luteinising Hormone (LH) From 0 Hour to 2 Hours Post-injection on Day 1 and Day 169
Time frame:
on Days 1 and 169
Reported as:
Number · percentage of participants
Percentage of Participants Showing ≤ 1.0 IU/L Increase in Serum Luteinising Hormone (LH) From 0 Hour to 2 Hours Post-injection on Day 1 and Day 169
percentage of participantsTriptorelin Embonate 22.5 mg
on Day 1 (n=118)0.85 (0.02 to 4.63)
on Day 169 (n=115)87.83 (80.42 to 93.18)
SecondaryPercentage Change From Baseline in Prostate Specific Antigen (PSA) Through Day 337
Time frame:
Baseline through Day 337
Reported as:
Mean · percentage of change in PSA levels
Percentage Change From Baseline in Prostate Specific Antigen (PSA) Through Day 337
percentage of change in PSA levelsTriptorelin Embonate 22.5 mg
at Day 85 (n=119)-83.20 ± 38.10
at Day 169 (n=117)-83.48 ± 38.29
at Day 253 (n=114)-85.43 ± 33.94
at Day 337 (n=113)-82.89 ± 40.74
SecondaryNumber of Participants Who Presented a Real "Acute-on-chronic" (AOC) Phenomenon (Testosterone Levels ≥ 1.735 Nmol/L 48 Hours After the Second Injection While Previously Castrated)
Time frame:
Day 171
Reported as:
Number · participants
Number of Participants Who Presented a Real "Acute-on-chronic" (AOC) Phenomenon (Testosterone Levels ≥ 1.735 Nmol/L 48 Hours After the Second Injection While Previously Castrated)
participantsTriptorelin Embonate 22.5 mg
Number of Participants Who Presented a Real "Acute-on-chronic" (AOC) Phenomenon (Testosterone Levels ≥ 1.735 Nmol/L 48 Hours After the Second Injection While Previously Castrated)1
SecondaryTestosterone Pharmacodynamic (PD) Metrics for First Injection: Area Under the Concentration vs Time Curve (AUC)
Time frame:
Days 1-169
Reported as:
Geometric mean · day*nmol/L
Testosterone Pharmacodynamic (PD) Metrics for First Injection: Area Under the Concentration vs Time Curve (AUC)
day*nmol/LPK/PD Subset
Testosterone Pharmacodynamic (PD) Metrics for First Injection: Area Under the Concentration vs Time Curve (AUC)224.13 (175.82 to 285.72)
SecondaryTestosterone PD Metrics for First Injection: Maximum Concentration (Cmax)
Time frame:
Days 1-169
Reported as:
Geometric mean · nmol/L
Testosterone PD Metrics for First Injection: Maximum Concentration (Cmax)
nmol/LPK/PD Subset
Testosterone PD Metrics for First Injection: Maximum Concentration (Cmax)16.52 (12.74 to 21.41)
SecondaryTestosterone PD Metrics for First Injection: Time to Peak Serum/Plasma Concentration (Tmax)
Time frame:
Days 1-169
Reported as:
Median · hours
Testosterone PD Metrics for First Injection: Time to Peak Serum/Plasma Concentration (Tmax)
hoursPK/PD Subset
Testosterone PD Metrics for First Injection: Time to Peak Serum/Plasma Concentration (Tmax)48 ± 40.02
SecondaryTestosterone PD Metrics for First Injection: Time to Castration (Tcast)
Time frame:
Days 1-169
Reported as:
Geometric mean · days
Testosterone PD Metrics for First Injection: Time to Castration (Tcast)
daysPK/PD Subset
Testosterone PD Metrics for First Injection: Time to Castration (Tcast)18.01 (16.45 to 19.72)
SecondaryTriptorelin PK Metrics for Both Injections: Area Under the Concentration vs Time Curve (AUC)
Time frame:
Days 1-169 and Days 169-337
Reported as:
Geometric mean · days * ng/mL
Triptorelin PK Metrics for Both Injections: Area Under the Concentration vs Time Curve (AUC)
days * ng/mLPK/PD Subset
AUC(1-169)61.30 (53.50 to 70.25)
AUC(169-337)66.44 (58.99 to 74.82)
SecondaryTriptorelin PK Metrics for Both Injections: Cmax
Time frame:
Days 1-169 and Days 169-337
Reported as:
Geometric mean · ng/mL
Triptorelin PK Metrics for Both Injections: Cmax
ng/mLPK/PD Subset of 15 Participants
Days 1-16916.77 (13.33 to 21.09)
Days 169-33718.09 (14.11 to 23.20)
SecondaryTriptorelin PK Metrics for Both Injections: Concentration 0 Hour
Time frame:
Days 1-169 and Days 169-337
Reported as:
Geometric mean · ng/mL
Triptorelin PK Metrics for Both Injections: Concentration 0 Hour
ng/mLPK/PD Subset
Days 1-1690.04 (0.02 to 0.09)
Days 169-3370.07 (0.04 to 0.11)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triptorelin Embonate 22.5 mg—17/120 (14.2%)117/120 (97.5%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventTriptorelin Embonate 22.5 mg
Atrial fibrillationCardiac disorders3/120
HyperglycaemiaEndocrine disorders2/120
Myocardial ischaemiaCardiac disorders2/120
Acute myocardial infarctionCardiac disorders1/120
AnaemiaBlood and lymphatic system disorders1/120
BronchitisRespiratory, thoracic and mediastinal disorders1/120
Colon cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/120
CystitisInfections and infestations1/120
DeathGeneral disorders1/120
Deep vein thrombosisBlood and lymphatic system disorders1/120
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTriptorelin Embonate 22.5 mg
Hot flushVascular disorders86/120
HypertensionVascular disorders14/120
Urinary tract infectionInfections and infestations13/120
ConstipationGastrointestinal disorders11/120
LethargyGeneral disorders11/120
ArthralgiaMusculoskeletal and connective tissue disorders10/120
Erectile dysfunctionReproductive system and breast disorders10/120
Back painMusculoskeletal and connective tissue disorders9/120
Upper respiratory tract infectionInfections and infestations8/120
MyalgiaMusculoskeletal and connective tissue disorders6/120

Baseline characteristics

Safety Analysis Set, defined as all enrolled subjects who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(years)Triptorelin Embonate 22.5 mg
Mean72.23 ± 7.32
Sex: Female, Male
Sex: Female, Male(Participants)Triptorelin Embonate 22.5 mg
Female0
Male120
Region of Enrollment
Region of Enrollment(participants)Triptorelin Embonate 22.5 mg
South Africa120
08

Study locations

10 sites
  • Paarl Medical Centre
    Paarl, Cape Town, Western Cape 7646, South Africa
  • Vergelegen Medi-Clinic
    Somerset West, Cape Town 7130, South Africa
  • Department of Urology, Tygerberg Hospital
    Tygerberg, Cape Town 7505, South Africa
  • JCM Bahlmann
    George, Eastern Cape 6530, South Africa
  • East Rand Urology Research Unit, Clinix Private Clinic
    Johannesburg, Gautang 1475, South Africa
  • Clinresco Centres (Pty) Ltd
    Kempton Park, Gauteng 1619, South Africa
  • Clinical Trial Unit, Room 2-54, Prinshof Medical Campus
    Pretoria, Gauteng 0002, South Africa
  • Pretoria Urology Hospital
    Pretoria, Gauteng 0028, South Africa
  • Wilmed Park Hospital
    Klerksdorp, North West Province 2571, South Africa
  • New Groote Schuur Hospital, Division of Urology
    Cape Town, 7925, South Africa
09

References and documents

Publications

  • Klippel KF, Winkler CJ, Jocham D, Rubben H, Moser B, Gulati A. [Effectiveness and tolerance of 1 dosage forms (subcutaneous and intramuscular) of decapeptyl depot in patients with advanced prostate carcinoma]. Urologe A. 1999 May;38(3):270-5. doi: 10.1007/s001200050280. German. PubMed 10407987 ↗
  • Tornoe CW, Agerso H, Senderovitz T, Nielsen HA, Madsen H, Karlsson MO, Jonsson EN. Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues. Br J Clin Pharmacol. 2007 Jun;63(6):648-64. doi: 10.1111/j.1365-2125.2006.02820.x. Epub 2006 Nov 10. PubMed 17096678 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2012
First posted
Aug 2, 2012
Start
Jul 2012
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Sep 15, 2015
Last update
Sep 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01656161
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Aug 2, 2012
Start date
Jul 2012
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Sep 15, 2015
Last update
Sep 15, 2015

Study contacts

Eija Lundstrom, MD
study director · Debiopharm SA
J. Bahlmann, MD
principal investigator · Private Practitioner

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion